Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18173744 | 0.82 | PLCG1 (0.53) | PLCG1KMT2AMEN1NOX1CA12 | |
| SCHEMBL18173666 | 0.79 | PLCG1 (0.45) | PLCG1KMT2AMEN1NOX1SRC | |
| SCHEMBL18173621 | 0.79 | PLCG1 (0.53) | PLCG1KMT2AMEN1NOX1SRC | |
| SCHEMBL88748 | 0.78 | PLCG1 (1.00) | PLCG1KMT2AMEN1NOX1CA12 | |
| SCHEMBL88913 | 0.77 | PLCG1 (0.65) | PLCG1KMT2AMEN1NOX1CA12 | |
| SCHEMBL13938220 | 0.73 | PLCG1 (0.59) | PLCG1KMT2AMEN1NOX1CA12 | |
| SCHEMBL29489792 | 0.72 | KMT2A (1.00) | PLCG1KMT2AMEN1NOX1CA12 | |
| SCHEMBL1021854 | 0.72 | KMT2A (1.00) | PLCG1KMT2AMEN1NOX1CA12 | |
| SCHEMBL20644286 | 0.69 | PLCG1 (0.41) | PLCG1KMT2AMEN1CA12CA1 | |
| SCHEMBL9001235 | 0.69 | NOTUM (0.50) | PLCG1KMT2AMEN1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3250035-B1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS INC (TW) | 2023-01-25 | — | — | EP | disclosed |
| US-10870635-B2 | Compounds and their use as BACE1 inhibitors | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2020-12-22 | — | — | US | disclosed |
| US-20180201604-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2018-07-19 | — | — | US | disclosed |
| EP-3250035-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | Allgenesis Biotherapeutics Inc. (TW) | 2017-12-06 | — | — | EP | disclosed |
| WO-2016172255-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10870635-B2 | Compounds and their use as BACE1 inhibitors | BACE1, BACE2, APP | PLCG1 3539/4885KMT2A 3744/4885MEN1 1510/4885 |
| US-20180201604-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | BACE1, BACE2, APP | PLCG1 3592/4885KMT2A 3811/4885MEN1 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.